IP Library Granted Patent US 9,314,420
Granted Patent B2
US 9,314,420 · App. 13/617,150 · Granted Apr 19, 2016

Acellular bioabsorbable tissue regeneration matrices

Inventor: Jan-Eric Ahlfors (St. John's, AG)
A61K9/0002A61K35/30A61K35/545A61K38/16A61K38/385A61K38/40A61K38/51A61K39/395A61K45/00A61L27/3604A61L27/3683A61L27/38A61L27/58A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,420
App. No.
13/617,150
Granted
Apr 19, 2016
Kind
B2
Abstract

The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.

Claims (22)

1. An isolated acellular bioabsorbable tissue regeneration matrix derived from blood or bone marrow comprising a heterogeneous mixture of proteins and salts, wherein the overall protein content of the matrix is at least 1%, wherein the matrix is characterized by

aggregates of spherical structures with a diameter of approximately at least 100 nm, wherein the acellular bioabsorbable tissue regeneration matrix lacks substantial metabolic activity as compared to that initially present in blood or bone marrow; and further wherein the acellular bioabsorbable tissue regeneration matrix is capable of initiating tissue regeneration in a subject with tissue damage, increasing tissue regeneration in a subject with tissue damage compared with untreated tissue, or both.

2. The isolated acellular bioabsorbable tissue regeneration matrix of claim 1 , further comprising one or more proteins selected from the group consisting of: transferrin, serum albumin, serum albumin precursor, complement component 3, chains A-D hemoglobin, IgM, IgG1, medullasin inhibitor 2, carbonic anhydrase, CA1 protein, and combinations thereof.

3. The isolated acellular bioabsorbable tissue regeneration matrix of claim 1 , wherein the spherical structures are recognized by CD56 antibodies.

4. The acellular bioabsorbable tissue regeneration matrix of claim 1 , wherein the spherical structures have a diameter of about 1-2 μm.

5. The acellular bioabsorbable tissue regeneration matrix of claim 1 , wherein the spherical structures have a diameter of about 2-4 μm.

6. The acellular bioabsorbable tissue regeneration matrix of claim 1 , further comprising a therapeutic agent.

7. The acellular bioabsorbable tissue regeneration matrix of claim 6 , wherein the therapeutic agent is distributed heterogeneously within the acellular bioabsorbable tissue regeneration matrix.

8. The acellular bioabsorbable tissue regeneration matrix of claim 6 , wherein the therapeutic agent is distributed homogeneously within the acellular bioabsorbable tissue regeneration matrix.

9. The acellular bioabsorbable tissue regeneration matrix of claim 6 , wherein the acellular bioabsorbable tissue regeneration matrix comprises two or more therapeutic agents.

10. The acellular bioabsorbable tissue regeneration matrix of claim 6 , wherein the therapeutic agent is selected from the group consisting of: proteins, peptides, drugs, cytokines, extracellular matrix molecules, growth factors, and combinations thereof.

11. The acellular bioabsorbable tissue regeneration matrix of claim 10 , wherein the acellular bioabsorbable tissue regeneration matrix increases the magnitude of one or more beneficial effects of the therapeutic agent.

12. The acellular bioabsorbable tissue regeneration matrix of claim 10 , wherein the acellular bioabsorbable tissue regeneration matrix prolongs one or more beneficial effects of the therapeutic agent by slowly releasing the therapeutic agent over time in the subject.

13. The acellular bioabsorbable tissue regeneration matrix of claim 10 , wherein the acellular bioabsorbable tissue regeneration matrix protects one or more beneficial effects of the therapeutic agent from substantially decreasing over time.

14. The acellular bioabsorbable tissue regeneration matrix of claim 1 , further comprising exogenous cells that have been added to the matrix.

15. The acellular bioabsorbable tissue regeneration matrix of claim 14 , wherein the cells are selected from the group consisting of: stem cells, progenitor cells, somatic cells, and combinations thereof.

16. The acellular bioabsorbable tissue regeneration matrix of claim 14 , wherein the cells are cells selected from the group consisting of: embryonic stem cells, neural stem cells, neuroprogenitor cells, neurons, glial cells, and combinations thereof.

17. The acellular bioabsorbable regeneration matrix of claim 1 , comprising fibers interspersed throughout the aggregates.

18. The acellular bioabsorbable regeneration matrix of claim 1 , wherein the matrix is self-assembled.

19. The acellular bioabsorbable regeneration matrix of claim 1 , wherein said regeneration matrix is in solid or semi-solid form, in the form of a three-dimensional matrix or in the form of a suspension.

20. The acellular bioabsorbable regeneration matrix of claim 1 , wherein the aggregates of spherical structures are 100 nm-4 microns in diameter.

21. The acellular bioabsorbable regeneration matrix of claim 1 , wherein the matrix further comprises lipids, carbohydrates and/or nucleic acids.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 9, 2017
From: AHLFORS, JAN-ERIC W
To: GENESIS TECHNOLOGIES LIMITED
Reel/Frame 042658/0114 →
Continuity (3)
Division 11588840 · Oct 26, 2006
Provisional Application 60730614 · Oct 26, 2005
Related Publication 20130136796A1 · May 30, 2013